MCID: SLV002
MIFTS: 61

Salivary Gland Cancer

Categories: Oral diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Salivary Gland Cancer

MalaCards integrated aliases for Salivary Gland Cancer:

Name: Salivary Gland Cancer 12 37 55 43 15
Malignant Neoplasm of Salivary Gland 12 73
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Salivary Gland Neoplasms 73
Salivary Gland Neoplasm 29

Classifications:



External Ids:

Disease Ontology 12 DOID:8850
ICD10 33 C08
ICD9CM 35 142.8
SNOMED-CT 68 187648003
KEGG 37 H01508

Summaries for Salivary Gland Cancer

MedlinePlus : 43 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Salivary Gland Cancer, also known as malignant neoplasm of salivary gland, is related to adenoid cystic carcinoma and oral cancer, and has symptoms including halitosis and snoring. An important gene associated with Salivary Gland Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and Innate Immune System. The drugs Cisplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include the salivary gl, salivary gland and lung, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Related Diseases for Salivary Gland Cancer

Diseases in the Salivary Gland Cancer family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 adenoid cystic carcinoma 29.9 AKT1 ERBB2 PTEN SERPINB5
2 oral cancer 29.7 CASP3 EGFR MMP2 MMP9
3 mucoepidermoid carcinoma 29.5 AREG CRTC1 EGFR ERBB2 MAML2
4 brain cancer 29.2 AKT1 CASP3 CASP8 EGFR PTEN STAT3
5 breast cancer 25.3 AKT1 AREG BIRC5 CASP3 CASP8 EGFR
6 salivary gland cancer, adult 12.4
7 salivary gland cancer, childhood 12.1
8 brooke-spiegler syndrome 11.1
9 pleomorphic adenoma 11.1
10 sublingual gland cancer 11.0
11 parotid gland cancer 11.0
12 breast intraductal proliferative lesion 10.8 EGFR ERBB2
13 intracystic papillary adenoma 10.7 EGFR ERBB2
14 extracranial arteriovenous malformation 10.7 MMP2 MMP9
15 progesterone-receptor negative breast cancer 10.6 EGFR ERBB2
16 breast scirrhous carcinoma 10.6 EGFR ERBB2
17 giant cell glioblastoma 10.6 EGFR PPARG PTEN
18 breast carcinoma in situ 10.6 EGFR ERBB2 MET
19 vulvar intraepithelial neoplasia 10.6 BIRC5 MMP2
20 differentiated thyroid carcinoma 10.6 EGFR MET PPARG
21 chordoma 10.5 EGFR MET PTEN
22 apical myocardial infarction 10.5 AKT1 MMP2 STAT3
23 estrogen-receptor positive breast cancer 10.5 AKT1 EGFR ERBB2
24 lentigo maligna melanoma 10.5 MMP2 MMP9
25 ductal carcinoma in situ 10.5 AKT1 EGFR ERBB2
26 villous adenocarcinoma 10.5 EGFR MMP2 MMP9
27 renal cell carcinoma, papillary, 1 10.5 ERBB2 MET PTEN
28 peripheral nervous system neoplasm 10.5 AKT1 CASP3 CASP8
29 anaplastic thyroid cancer 10.5 CASP3 MET PTEN
30 autonomic nervous system neoplasm 10.5 AKT1 CASP3 CASP8
31 helicobacter pylori infection 10.4 CASP3 EGFR MET
32 serous cystadenocarcinoma 10.4 AKT1 ERBB2 MMP2
33 breast ductal carcinoma 10.4 EGFR ERBB2 MET
34 uterine carcinosarcoma 10.4 EGFR ERBB2 PTEN
35 arteries, anomalies of 10.4 AKT1 MMP9 PPARG
36 psammomatous meningioma 10.4 MMP2 MMP9
37 adult astrocytic tumour 10.3 MMP7 MMP9 PTEN
38 endometrial adenocarcinoma 10.3 AKT1 EGFR ERBB2 PTEN
39 focal myositis 10.3 MMP2 MMP7 MMP9
40 spastic entropion 10.3 MMP2 MMP7 MMP9
41 senile ectropion 10.3 MMP2 MMP7 MMP9
42 light chain deposition disease 10.3 MMP2 MMP7 MMP9
43 cowden syndrome 1 10.3 EGFR PTEN
44 myeloma, multiple 10.2 AKT1 CASP3 CASP8 STAT3
45 grade iii astrocytoma 10.2 EGFR MMP2 MMP9 PTEN
46 pharynx cancer 10.2 AKT1 CASP3 EGFR MMP9
47 varicose veins 10.2 MMP2 MMP7 MMP9
48 lacrimal gland mucoepidermoid carcinoma 10.2 CRTC1 MAML2
49 cutaneous mucoepidermoid carcinoma 10.1 CRTC1 MAML2
50 transitional cell carcinoma 10.1 EGFR ERBB2 PTEN

Graphical network of the top 20 diseases related to Salivary Gland Cancer:



Diseases related to Salivary Gland Cancer

Symptoms & Phenotypes for Salivary Gland Cancer

UMLS symptoms related to Salivary Gland Cancer:


halitosis, snoring

GenomeRNAi Phenotypes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.46 CASP3 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 9.46 EGFR
3 Increased cell viability after pRB stimulation GR00230-A-1 9.26 AKT1 EGFR ERBB2 MET
4 Reduced mammosphere formation GR00396-S 9.17 MMP7 PPARG PTEN STAT3 BIRC5 EGFR

MGI Mouse Phenotypes related to Salivary Gland Cancer:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 ERBB2 EGFR CASP8 ID1 MET ISL1
2 growth/size/body region MP:0005378 10.5 CRTC1 ERBB2 EGFR CASP8 ID1 ISL1
3 cellular MP:0005384 10.48 CASP8 EGFR ISL1 ID1 ERBB2 MMP9
4 hematopoietic system MP:0005397 10.46 CRTC1 EGFR CASP8 ID1 MMP9 MMP2
5 homeostasis/metabolism MP:0005376 10.45 EGFR CASP8 CRTC1 ISL1 ERBB2 MMP9
6 immune system MP:0005387 10.44 CRTC1 EGFR CASP8 ID1 ISL1 MMP9
7 endocrine/exocrine gland MP:0005379 10.42 CRTC1 ERBB2 EGFR CASP8 ID1 ISL1
8 mortality/aging MP:0010768 10.42 EGFR CASP8 ID1 ERBB2 ISL1 MMP9
9 behavior/neurological MP:0005386 10.36 CRTC1 CASP3 ISL1 ERBB2 MET PTEN
10 embryo MP:0005380 10.36 CASP8 EGFR ISL1 ID1 ERBB2 MET
11 digestive/alimentary MP:0005381 10.33 EGFR ISL1 ID1 ERBB2 MMP9 MET
12 muscle MP:0005369 10.29 ERBB2 EGFR CASP8 ID1 MET ISL1
13 neoplasm MP:0002006 10.27 ERBB2 EGFR CASP8 ID1 MET ISL1
14 integument MP:0010771 10.26 EGFR CASP8 ISL1 ERBB2 MMP9 PPARG
15 nervous system MP:0003631 10.25 CASP8 EGFR ISL1 ID1 ERBB2 MMP2
16 adipose tissue MP:0005375 10.17 EGFR CRTC1 PTEN PPARG SERPINB5 STAT3
17 craniofacial MP:0005382 10.14 EGFR CASP3 ERBB2 ISL1 MET MMP2
18 liver/biliary system MP:0005370 10.11 CASP8 EGFR ID1 MET PTEN PPARG
19 normal MP:0002873 10.11 EGFR ISL1 ERBB2 MMP2 MET PTEN
20 renal/urinary system MP:0005367 10.06 CASP8 EGFR ID1 ISL1 MMP9 MET
21 reproductive system MP:0005389 10.03 EGFR CRTC1 ISL1 ID1 ERBB2 MMP9
22 no phenotypic analysis MP:0003012 9.95 EGFR CASP3 ISL1 ID1 MET PPARG
23 respiratory system MP:0005388 9.9 CASP8 EGFR ID1 ERBB2 MMP9 MMP2
24 skeleton MP:0005390 9.7 EGFR ISL1 ID1 ERBB2 MMP2 PTEN
25 vision/eye MP:0005391 9.4 EGFR ID1 ISL1 MMP9 MMP2 MET

Drugs & Therapeutics for Salivary Gland Cancer

Drugs for Salivary Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Iodine Approved, Investigational Phase 3 7553-56-2 807
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
7
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
10
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
leucovorin Approved, Nutraceutical Phase 3,Phase 1 58-05-9 143 6006
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 cadexomer iodine Phase 3
18 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2,Not Applicable
19 Neurotransmitter Agents Phase 3,Phase 2
20 Dermatologic Agents Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 3,Phase 2
22 Pharmaceutical Solutions Phase 3
23 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
24 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
25 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
26 Antimetabolites Phase 3,Phase 1,Phase 2
27 Autonomic Agents Phase 3,Phase 2
28 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
29 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Not Applicable
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Analgesics Phase 3,Phase 2
33 Central Nervous System Depressants Phase 3
34 Adjuvants, Anesthesia Phase 3
35 Folic Acid Antagonists Phase 3,Phase 1
36 Mitogens Phase 3,Phase 2,Phase 1
37 Cholinergic Agents Phase 3,Phase 2
38 Narcotics Phase 3
39 Histamine Antagonists Phase 3
40 Analgesics, Opioid Phase 3
41 Anesthetics Phase 3
42 Anesthetics, General Phase 3
43 Anesthetics, Intravenous Phase 3
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1
45 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
46 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Endothelial Growth Factors Phase 3,Phase 1
48 Vitamin B Complex Phase 3,Phase 2,Phase 1
49 Antibodies Phase 3,Phase 2,Phase 1
50 Immunoglobulins Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
2 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
3 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
8 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
9 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
10 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
11 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
12 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
13 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
14 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
15 Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck Unknown status NCT02558387 Phase 2 BIBF1120
16 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2 Sorafenib
17 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Unknown status NCT02857712 Phase 2 Axitinib
18 CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC Unknown status NCT01154270 Phase 2
19 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
20 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
21 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
22 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
23 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
24 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
25 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Completed NCT01613768 Phase 2 eribulin mesylate
26 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
27 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
28 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
29 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
30 A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Completed NCT01488838 Phase 2 Cisplatin: 40 mg/m2 weekly during radiation
31 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
32 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
33 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
34 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
35 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
36 Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma Completed NCT00228488 Phase 2 Gefitinib
37 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
38 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
39 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
40 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
41 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
42 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
43 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
44 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
45 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
46 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
47 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
48 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
49 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
50 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride

Search NIH Clinical Center for Salivary Gland Cancer

Genetic Tests for Salivary Gland Cancer

Genetic tests related to Salivary Gland Cancer:

# Genetic test Affiliating Genes
1 Salivary Gland Neoplasm 29

Anatomical Context for Salivary Gland Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Cancer:

19
The Salivary Gl

MalaCards organs/tissues related to Salivary Gland Cancer:

41
Salivary Gland, Lung, Testes, Brain, Liver, Thyroid, Breast

Publications for Salivary Gland Cancer

Articles related to Salivary Gland Cancer:

(show top 50) (show all 137)
# Title Authors Year
1
Development of a novel salivary gland cancer lymph node staging system. ( 29742277 )
2018
2
Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer. ( 29949051 )
2018
3
AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report. ( 29873033 )
2018
4
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. ( 29044862 )
2018
5
Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2A N0 high-grade salivary gland cancer. ( 29925355 )
2018
6
Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. ( 29555661 )
2018
7
Treatment Times in Salivary Gland Cancer: National Patterns and Association with Survival. ( 29460669 )
2018
8
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). ( 28102887 )
2017
9
Androgen Receptor Signaling in Salivary Gland Cancer. ( 28208703 )
2017
10
Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study. ( 28160551 )
2017
11
Effective nasal mask ventilation of a difficult airway in a patient with advanced salivary gland cancer. ( 28494881 )
2017
12
The rising incidence of major salivary gland cancer in the United States. ( 28346649 )
2017
13
Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. ( 28819427 )
2017
14
A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. ( 28133481 )
2017
15
Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. ( 28401485 )
2017
16
Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. ( 28881386 )
2017
17
Immunohistochemical and molecular profile of salivary gland cancer in children. ( 28139061 )
2017
18
(A+)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. ( 27670669 )
2016
19
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. ( 28006087 )
2016
20
Unmet needs for patients with salivary gland cancer. ( 27377424 )
2016
21
Targeting ID2 expression triggers a more differentiated phenotype and reduces aggressiveness in human salivary gland cancer cells. ( 27364596 )
2016
22
ID1 Controls Aggressiveness of Salivary Gland Cancer Cells via Crosstalk of IGF and AKT Pathways. ( 27466488 )
2016
23
The MMP-2 and MMP-9 promoter polymorphisms and susceptibility to salivary gland cancer. ( 27569079 )
2016
24
Incidence and risk factors of late recurrence in patients with salivary gland cancer. ( 27960047 )
2016
25
High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. ( 26841273 )
2016
26
Cytomegalovirus induces Interleukin-6 mediated inflammatory response in salivary gland cancer. ( 28039719 )
2016
27
Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. ( 26661925 )
2015
28
An epidemiological evaluation of salivary gland cancer in the Netherlands (1989-2010). ( 25454260 )
2015
29
Outcomes and prognostic factors in modern era management of major salivary gland cancer. ( 26033470 )
2015
30
Increased risk of salivary gland cancer among women with a previous cancer diagnosis. ( 25581457 )
2015
31
Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers. ( 26252941 )
2015
32
Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia-1. ( 25914292 )
2015
33
Familial predisposition for salivary gland cancer in Finland. ( 24701124 )
2014
34
Overview of major salivary gland cancer surgery in Ontario (2003A?2010). ( 25492404 )
2014
35
Racial and Ethnic Disparities in Salivary Gland Cancer Survival. ( 24744112 )
2014
36
Salivary Gland Cancer in BRCA-Positive Families : A Retrospective Review. ( 25257187 )
2014
37
The Impact of Demographic and Socioeconomic Factors on Major Salivary Gland Cancer Survival. ( 24647644 )
2014
38
Salivary gland cancer risk and BRCA gene mutations may be linked, study finds. ( 25577819 )
2014
39
Retracted: the oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. ( 25610927 )
2014
40
Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. ( 22836059 )
2013
41
Predictors of cervical lymph node metastasis in salivary gland cancer. ( 23780687 )
2013
42
Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. ( 23517130 )
2013
43
Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo. ( 24398788 )
2013
44
Salivary gland cancer: an update on present and emerging therapies. ( 23714518 )
2013
45
Salivary gland cancer stem cells. ( 23810400 )
2013
46
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. ( 23242174 )
2013
47
The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation. ( 23608756 )
2013
48
Expression and function of CXCR4 in human salivary gland cancers. ( 22847686 )
2013
49
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. ( 23611358 )
2013
50
Recurrent salivary gland cancer. ( 22215326 )
2012

Variations for Salivary Gland Cancer

Expression for Salivary Gland Cancer

Search GEO for disease gene expression data for Salivary Gland Cancer.

Pathways for Salivary Gland Cancer

Pathways related to Salivary Gland Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 AKT1 BIRC5 CASP3 CASP8 EGFR ERBB2
2
Show member pathways
13.94 AKT1 AREG CASP3 CASP8 EGFR ERBB2
3
Show member pathways
13.78 AKT1 AREG BIRC5 EGFR ERBB2 MET
4
Show member pathways
13.57 AKT1 EGFR ERBB2 MET MMP2 MMP9
5
Show member pathways
13.48 AKT1 CASP3 EGFR MMP2 MMP7 MMP9
6
Show member pathways
13.48 AKT1 AREG CASP3 EGFR ERBB2 MET
7
Show member pathways
13.42 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
8
Show member pathways
13.36 AKT1 AREG CASP3 CASP8 EGFR ERBB2
9
Show member pathways
13.34 AKT1 AREG CASP3 CASP8 EGFR ERBB2
10
Show member pathways
13.08 AKT1 CASP3 CASP8 ISL1 MET STAT3
11
Show member pathways
12.97 AKT1 EGFR ERBB2 MET PTEN STAT3
12
Show member pathways
12.96 AKT1 EGFR ERBB2 MET PTEN STAT3
13
Show member pathways
12.91 AKT1 AREG CASP3 CASP8 EGFR ERBB2
14
Show member pathways
12.86 AKT1 AREG EGFR ERBB2 PTEN STAT3
15
Show member pathways
12.83 AKT1 EGFR ERBB2 MET PTEN
16 12.82 AKT1 AREG CASP3 CASP8 EGFR ERBB2
17
Show member pathways
12.81 AKT1 AREG BIRC5 CASP3 EGFR ERBB2
18
Show member pathways
12.79 AKT1 EGFR ERBB2 MET PTEN
19
Show member pathways
12.79 AKT1 CASP3 ERBB2 MET PTEN STAT3
20
Show member pathways
12.75 AKT1 EGFR ERBB2 MET MMP2 MMP9
21
Show member pathways
12.74 AKT1 CASP3 CASP8 EGFR MMP2 PTEN
22
Show member pathways
12.66 AKT1 BIRC5 EGFR ERBB2 MMP2 STAT3
23
Show member pathways
12.6 AKT1 BIRC5 CASP3 CASP8 MMP9 PTEN
24
Show member pathways
12.56 AKT1 EGFR ERBB2 MET PTEN
25
Show member pathways
12.55 AKT1 CASP3 ERBB2 PTEN STAT3
26
Show member pathways
12.55 AKT1 AREG EGFR ERBB2 MET STAT3
27
Show member pathways
12.5 AKT1 CASP3 CASP8 EGFR ERBB2 MET
28 12.48 CASP3 EGFR ERBB2 MET MMP9 PTEN
29 12.45 AKT1 BIRC5 CASP3 CASP8 EGFR ERBB2
30
Show member pathways
12.43 CASP3 CASP8 PTEN SERPINB5
31
Show member pathways
12.4 AKT1 CASP3 CASP8 MMP9 STAT3
32
Show member pathways
12.4 AKT1 AREG CASP3 CASP8 EGFR ERBB2
33
Show member pathways
12.38 AKT1 EGFR ERBB2 PPARG
34
Show member pathways
12.32 AKT1 CASP3 CASP8 PTEN
35
Show member pathways
12.32 AKT1 CASP3 CASP8 STAT3
36 12.31 BIRC5 CASP3 CASP8 SERPINB5
37
Show member pathways
12.3 AKT1 AREG EGFR PTEN
38
Show member pathways
12.28 AKT1 CASP3 PPARG STAT3
39 12.26 AKT1 EGFR ERBB2 PTEN STAT3
40 12.23 AKT1 CASP3 EGFR ERBB2 MET MMP2
41 12.22 AKT1 CASP3 CASP8 EGFR PTEN
42
Show member pathways
12.21 AKT1 EGFR ERBB2 PTEN STAT3
43 12.2 AKT1 CASP3 EGFR ERBB2 MET PTEN
44 12.18 AKT1 CASP3 CRTC1 STAT3
45
Show member pathways
12.15 AKT1 AREG EGFR MET STAT3
46 12.15 AKT1 ID1 ISL1 STAT3
47
Show member pathways
12.15 AKT1 EGFR PTEN STAT3
48 12.14 EGFR MET MMP2 PTEN SERPINB5
49
Show member pathways
12.13 EGFR ERBB2 MET
50
Show member pathways
12.12 AKT1 EGFR ERBB2 STAT3

GO Terms for Salivary Gland Cancer

Cellular components related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 AKT1 AREG BIRC5 CASP3 CASP8 CRTC1
2 cytoplasm GO:0005737 9.55 AKT1 AREG BIRC5 CASP3 CASP8 CRTC1
3 basal plasma membrane GO:0009925 9.33 EGFR ERBB2 MET
4 death-inducing signaling complex GO:0031264 9.32 CASP3 CASP8
5 nucleoplasm GO:0005654 10 AKT1 BIRC5 CASP3 CASP8 CRTC1 ID1

Biological processes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 EGFR ERBB2 MET PTEN
2 positive regulation of cell proliferation GO:0008284 9.98 AKT1 AREG BIRC5 EGFR ISL1 PTEN
3 cytokine-mediated signaling pathway GO:0019221 9.93 AKT1 BIRC5 CASP3 MMP2 MMP9 STAT3
4 aging GO:0007568 9.92 AKT1 MMP7 PTEN STAT3
5 positive regulation of protein phosphorylation GO:0001934 9.91 AKT1 EGFR ERBB2 MMP9
6 wound healing GO:0042060 9.87 CASP3 EGFR ERBB2
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.87 CASP3 CASP8 PPARG
8 cellular response to insulin stimulus GO:0032869 9.86 AKT1 PPARG PTEN
9 extracellular matrix disassembly GO:0022617 9.85 MMP2 MMP7 MMP9
10 positive regulation of cell growth GO:0030307 9.85 AKT1 EGFR ERBB2
11 heart development GO:0007507 9.85 CASP3 ERBB2 ID1 ISL1 PPARG PTEN
12 positive regulation of kinase activity GO:0033674 9.83 EGFR ERBB2 MET
13 collagen catabolic process GO:0030574 9.83 MMP2 MMP7 MMP9
14 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 ID1
15 epidermal growth factor receptor signaling pathway GO:0007173 9.82 AKT1 AREG EGFR
16 cellular response to growth factor stimulus GO:0071363 9.81 AKT1 EGFR ERBB2
17 learning or memory GO:0007611 9.81 CASP3 EGFR PTEN
18 cellular response to mechanical stimulus GO:0071260 9.8 AKT1 CASP8 EGFR MMP7
19 cell proliferation GO:0008283 9.8 AKT1 AREG EGFR ERBB2 MET PTEN
20 cellular response to organic cyclic compound GO:0071407 9.78 AKT1 CASP3 CASP8 STAT3
21 execution phase of apoptosis GO:0097194 9.76 AKT1 CASP3 CASP8
22 cellular response to nerve growth factor stimulus GO:1990090 9.75 AKT1 ID1 PTEN
23 cellular response to reactive oxygen species GO:0034614 9.74 AKT1 EGFR MMP9
24 cellular response to cadmium ion GO:0071276 9.73 AKT1 EGFR MMP9
25 response to organic substance GO:0010033 9.72 AKT1 CASP3 PPARG PTEN STAT3
26 response to antibiotic GO:0046677 9.71 CASP3 CASP8 ID1
27 cellular response to epidermal growth factor stimulus GO:0071364 9.71 AKT1 EGFR ERBB2 ID1
28 negative regulation of ERBB signaling pathway GO:1901185 9.7 EGFR ERBB2
29 cellular response to peptide GO:1901653 9.7 AKT1 ID1
30 positive regulation of DNA binding GO:0043388 9.7 ISL1 MMP9 PPARG
31 endothelial cell morphogenesis GO:0001886 9.67 ID1 MET
32 negative regulation of cell size GO:0045792 9.67 AKT1 PTEN
33 cellular response to leptin stimulus GO:0044320 9.66 PTEN STAT3
34 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.64 AKT1 EGFR
35 response to estradiol GO:0032355 9.63 AREG CASP3 CASP8 EGFR PTEN STAT3
36 response to cobalt ion GO:0032025 9.62 CASP3 CASP8
37 negative regulation of protein homodimerization activity GO:0090074 9.61 ID1 ISL1
38 cellular response to decreased oxygen levels GO:0036294 9.59 AKT1 PTEN
39 response to UV-A GO:0070141 9.55 AKT1 EGFR
40 response to organic cyclic compound GO:0014070 9.5 AREG CASP3 EGFR ID1 PPARG PTEN
41 negative regulation of apoptotic process GO:0043066 9.32 AKT1 BIRC5 CASP3 EGFR ERBB2 ID1
42 transcription, DNA-templated GO:0006351 10.34 BIRC5 CRTC1 ERBB2 ID1 ISL1 MAML2
43 multicellular organism development GO:0007275 10.22 AKT1 EGFR ERBB2 ID1 ISL1 MET
44 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 AKT1 CRTC1 EGFR ISL1 MAML2 MET
45 positive regulation of gene expression GO:0010628 10.03 AKT1 ERBB2 ID1 PTEN STAT3
46 positive regulation of apoptotic process GO:0043065 10 AKT1 CASP3 MMP9 PPARG PTEN

Molecular functions related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.91 CASP3 CASP8 MMP2 MMP7 MMP9
2 protein dimerization activity GO:0046983 9.73 ERBB2 ID1 STAT3 TSC22D1
3 MAP kinase kinase kinase activity GO:0004709 9.67 EGFR ERBB2 MET
4 enzyme binding GO:0019899 9.65 AKT1 BIRC5 EGFR PPARG PTEN
5 mitogen-activated protein kinase kinase binding GO:0031434 9.63 EGFR ERBB2 MET
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 EGFR ERBB2 MET
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 EGFR ERBB2 MET
8 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.52 CASP3 CASP8
9 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.48 EGFR ERBB2
10 protein phosphatase binding GO:0019903 9.35 EGFR ERBB2 MET PPARG STAT3
11 nitric-oxide synthase regulator activity GO:0030235 9.32 AKT1 EGFR
12 identical protein binding GO:0042802 9.32 AKT1 BIRC5 CASP8 EGFR ERBB2 MET
13 protein binding GO:0005515 10.13 AKT1 AREG BIRC5 CASP3 CASP8 CRTC1

Sources for Salivary Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....